Metoprolol in the treatment of cardiovascular disease: a critical reappraisal

Research output: Contribution to journalReview article

Abstract

Background: Extensive clinical experience on metoprolol has been gained in different cardiovascular conditions. Review: This paper discusses the use of metoprolol, with a focus on the extended-release formulation, in clinical practice in the light of existing evidence and current recommendations. This is a narrative review based on existing evidence and clinical experience of the author. Evidence on the use of metoprolol in heart failure, ischemic artery disease, arterial hypertension, and atrial fibrillation is well-established. Conclusions: Metoprolol still appears to be a suitable pharmacological option in different cardiovascular conditions. Research on this molecule is still active and new, promising settings of use are being explored and may provide relevant results in the years to come.

Original languageEnglish
Pages (from-to)1635-1643
Number of pages9
JournalCurrent Medical Research and Opinion
Volume34
Issue number9
DOIs
Publication statusPublished - Sep 2 2018

Fingerprint

Metoprolol
Cardiovascular Diseases
Atrial Fibrillation
Heart Failure
Arteries
Pharmacology
Hypertension
Research

Keywords

  • Atrial fibrillation
  • congestive heart failure
  • essential hypertension
  • ischemic heart disease
  • metoprolol succinate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Metoprolol in the treatment of cardiovascular disease : a critical reappraisal. / Grassi, Guido.

In: Current Medical Research and Opinion, Vol. 34, No. 9, 02.09.2018, p. 1635-1643.

Research output: Contribution to journalReview article

@article{976c46b703b34a0885baa9a74a90ec78,
title = "Metoprolol in the treatment of cardiovascular disease: a critical reappraisal",
abstract = "Background: Extensive clinical experience on metoprolol has been gained in different cardiovascular conditions. Review: This paper discusses the use of metoprolol, with a focus on the extended-release formulation, in clinical practice in the light of existing evidence and current recommendations. This is a narrative review based on existing evidence and clinical experience of the author. Evidence on the use of metoprolol in heart failure, ischemic artery disease, arterial hypertension, and atrial fibrillation is well-established. Conclusions: Metoprolol still appears to be a suitable pharmacological option in different cardiovascular conditions. Research on this molecule is still active and new, promising settings of use are being explored and may provide relevant results in the years to come.",
keywords = "Atrial fibrillation, congestive heart failure, essential hypertension, ischemic heart disease, metoprolol succinate",
author = "Guido Grassi",
year = "2018",
month = "9",
day = "2",
doi = "10.1080/03007995.2018.1479245",
language = "English",
volume = "34",
pages = "1635--1643",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Metoprolol in the treatment of cardiovascular disease

T2 - a critical reappraisal

AU - Grassi, Guido

PY - 2018/9/2

Y1 - 2018/9/2

N2 - Background: Extensive clinical experience on metoprolol has been gained in different cardiovascular conditions. Review: This paper discusses the use of metoprolol, with a focus on the extended-release formulation, in clinical practice in the light of existing evidence and current recommendations. This is a narrative review based on existing evidence and clinical experience of the author. Evidence on the use of metoprolol in heart failure, ischemic artery disease, arterial hypertension, and atrial fibrillation is well-established. Conclusions: Metoprolol still appears to be a suitable pharmacological option in different cardiovascular conditions. Research on this molecule is still active and new, promising settings of use are being explored and may provide relevant results in the years to come.

AB - Background: Extensive clinical experience on metoprolol has been gained in different cardiovascular conditions. Review: This paper discusses the use of metoprolol, with a focus on the extended-release formulation, in clinical practice in the light of existing evidence and current recommendations. This is a narrative review based on existing evidence and clinical experience of the author. Evidence on the use of metoprolol in heart failure, ischemic artery disease, arterial hypertension, and atrial fibrillation is well-established. Conclusions: Metoprolol still appears to be a suitable pharmacological option in different cardiovascular conditions. Research on this molecule is still active and new, promising settings of use are being explored and may provide relevant results in the years to come.

KW - Atrial fibrillation

KW - congestive heart failure

KW - essential hypertension

KW - ischemic heart disease

KW - metoprolol succinate

UR - http://www.scopus.com/inward/record.url?scp=85051528501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051528501&partnerID=8YFLogxK

U2 - 10.1080/03007995.2018.1479245

DO - 10.1080/03007995.2018.1479245

M3 - Review article

AN - SCOPUS:85051528501

VL - 34

SP - 1635

EP - 1643

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -